On June 2, 2021 BERG, a clinical-stage biotech that employs patient biology and artificial intelligence (AI) to research diseases and develop innovative treatments, reported results from a recently completed Phase 1 study of its investigational drug, BPM 31510 (novel ubidecarenone formulation) in recurrent glioblastoma multiforme (GBM) (Press release, Berg, JUN 2, 2021, View Source [SID1234583426]). The study will be presented at the 2021 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (ASCO) (Free ASCO Whitepaper) from June 4 – June 8, 2021, defining the details on identification of molecular analytes in plasma, buffy coat and urine and unveiling pathways to potentially predict clinically relevant responses to BPM 31510 in GBM patients undergoing treatment.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"At BERG, we want to remove the stigma that brain cancer is a death sentence," said Dr. Niven R. Narain, CEO, President and Co-founder of BERG. "The limited drugs available today may not work for a patient’s unique biological footprint. The results from our study offer hope to patients, and hold promise for BERG’s BPM 31510, solving a serious unmet need in medicine today."
GBM is the most aggressive, malignant primary brain tumor, averaging 12-18 months of survival time upon diagnosis with only 25% of GBM patients surviving more than one year. Today, GBM-related tumors account for 17% of all tumors of the brain, and tend to occur between the ages of 45 and 70.
The study was conducted in collaboration with Seema Nagpal, M.D. Clinical Associate Professor of Neurology & Neurological Sciences, and Lawrence Recht, M.D., Professor of Neurology & Neurological Sciences, both of Stanford University School of Medicine, in addition to other Stanford Medicine researchers and in collaboration with BERG.
Details of the BERG presentation:
Session title
Abstract title
Presenters
Dates
Central Nervous System Tumors
2059: Comprehensive molecular pharmacodynamic assessment identifies response markers of intermediary metabolism associated with BPM 31510-IV treatment in advanced glioblastoma multiforme patients
Seema Nagpal, Rangaprasad Sarangarajan, Can Bruce, Greg M Miller, Leonardo O Rodrigues, Punit Shah, Richard Searfoss, Kennedy Ofori-Mensa, Vladimir Tolstikov, Bennett Greenwood, Valerie Bussberg, Michael A. Kiebish, Elder Granger, Niven R. Narain, Lawrence David Recht; Stanford University, Stanford, CA; Berg LLC, Framingham, MA
June 4, 2021 – June 8, 2021
Digital Program:
E-Poster
The Abstract is available online: View Source, and the Poster will be available to registered 2021 ASCO (Free ASCO Whitepaper) Virtual Scientific Program attendees starting Friday, June 4th.
In its commitment to serve patients afflicted with cancer, BERG has collaborated on other projects with leading institutions like MD Anderson Cancer Institute (clinical trials) and Harvard/BIDMC (Project Survival), among others.